Mallinckrodt to Showcase Groundbreaking Research on TERLIVAZ® at the 2025 Digestive Disease Week Mallinckrodt plc will present significant research on its drug TERLIVAZ® at the 2025 DDW, focusing on hepatorenal syndrome and its effects on kidney function.

Mallinckrodt to Showcase Groundbreaking Research on TERLIVAZ® at the 2025 Digestive Disease Week #United_States #San_Diego #Mallinckrodt #TERLIVAZ #Digestive_Disease_Week

“To those about to use #terlipressin, we salute you”
#terlivaz #livertwitter onlinelibrary.wiley.com/doi/10.1111/apt.17195

Highlights of #terlipressin aka #terlivaz label are it’s limitations of use:
. Cr >5 unlikely to benefit
. Volume overloaded or those with 3 or more organ failures (ACLF-3) at high risk for respiratory failure
. Do not give is spO2 is or becomes under 90% #LiverTwitter